Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2 selinexor study in recurrent gliomas
NL-OMON42461Phase 2Active, not recruiting
- Sponsor
- Karyopharm Therapeutics Inc.
- Start
- May 2016
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of selinexor in glioblastoma (GBM), malignant glioma and anaplastic glioma (6 arms), sponsored by Karyopharm Therapeutics Inc. Primary endpoint: 6-month progression-free survival rate. Started May 2016; status: active, not recruiting.
02
Drugs
selinexor
03
Conditions
glioblastoma (GBM)malignant gliomaanaplastic glioma
Beyond the preview
Go deeper on NL-OMON42461.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON42461.